About the Authors
- Sylvain Rheims
-
Affiliations Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Lyon, France , CTRS INSERM-IDEE, Institute for Children and Adolescents with Epilepsy, Hospices Civils de Lyon, Lyon, France
- Michel Cucherat
-
Affiliation Department of Clinical Pharmacology, EA 643, Lyon-1 University, Laennec Faculty of Medicine, Lyon, France
- Alexis Arzimanoglou
-
Affiliations CTRS INSERM-IDEE, Institute for Children and Adolescents with Epilepsy, Hospices Civils de Lyon, Lyon, France , Department of Epileptology, Sleep and Pediatric Neurophysiology, Hospices Civils de Lyon, Lyon, France
- Philippe Ryvlin
-
*To whom correspondence should be addressed. E-mail: ryvlin@cermep.fr
Affiliations Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, Lyon, France , CTRS INSERM-IDEE, Institute for Children and Adolescents with Epilepsy, Hospices Civils de Lyon, Lyon, France , INSERM U821, Lyon, France
Competing Interests
SR has received speaker fees from Pfizer. MC has no conflict of interest. AA has received speaker or consultant fees from Pfizer, Sanofi-Aventis, GlaxoSmithKline (GSK), Jansen-Cilag, UCB Pharma, EISAI, and Valeant. PR has received speaker fees from Cyberonics, Eisai, GSK, Janssen-Cilag, Novartis, Pfizer, Sanofi-Synthelabo, and UCB; and consultant fees from Cyberonics, GSK, Janssen-Cilag, Novartis, Pfizer, UCB, and Valeant.